2024
Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
Iat A, Bewersdorf J, Gilhodes J, Liu Y, Shallis R, Boussi L, Zucenka A, Bystrom R, DeAngelo D, Berton G, Soua A, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Goldberg A, Zeidan A, Cluzeau T, Shimony S, Stahl M, Garciaz S. Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia. Blood 2024, 144: 1508. DOI: 10.1182/blood-2024-207045.Peer-Reviewed Original ResearchCumulative incidence of relapseRelapse-free survivalAcute myeloid leukemiaOverall response rateAdverse risk cytogeneticsAllo-SCTVEN-based therapyNon-relapse mortalityIntensive chemotherapyComposite CROverall survivalIC groupMedian OSMyeloid leukemiaElderly patientsTherapy-related acute myeloid leukemiaHigh-risk acute myeloid leukemiaAllogeneic stem-cell transplantationMedian time to relapseElderly acute myeloid leukemiaLong-term disease controlResponse rateFrequent cytogenetic alterationsProspective validation trialVIALE-A trial
2016
Disease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes
Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Disease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes. Cancer 2016, 122: 1598-1607. PMID: 26970288, PMCID: PMC5509410, DOI: 10.1002/cncr.29945.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeEligible patientsHazard ratioMedicare beneficiariesMultivariate Cox proportional hazards modelEnd Results-Medicare databasePropensity score-matched groupsCox proportional hazards modelOverall study populationSubgroup of patientsConfidence intervalsCost-saving interventionEnd of studyProportional hazards modelElderly patientsOverall survivalDisease characteristicsMDS cohortPatient outcomesStudy populationInternational ClassificationWarrants additional researchHazards modelPatientsSurvival rate